Comparing after-surgery treatments for HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This study looks at different treatment plans after surgery for people with HER2-positive breast cancer who still have cancer cells remaining after initial chemo and trastuzumab. It aims to see which approach helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer (a type that has too much of a protein called HER2).
- You received chemotherapy plus trastuzumab (Herceptin) before surgery, for at least 6 cycles.
- You had surgery to remove the tumor, and the pathology after surgery still found cancer cells in the breast or lymph nodes.
- Your hormone receptor status (whether your cancer uses hormones to grow) has been tested.
- Your cancer has not spread to distant organs (like bones, liver, or lungs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
This trial compares two treatment approaches in people with high-risk hormone-positive, HER2-negative breast cancer that has spread to certain lymph nodes. It looks at which option works best to lower cancer returning and to control the disease after surgery and initial chemotherapy.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.